Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Recurrent or Metastatic Cervical Cancer

NCT05557565 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05557565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05557565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Recurrent or Metastatic Cervical Cancer
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
December 21, 2021
Completion date
June 30, 2023
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer